Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Labcorp, Bio-Rad, Qiagen, Element Biosciences, Takara Bio, More

Labcorp Plasma Detect

Labcorp has launched Plasma Detect, a tumor-informed, whole-genome sequencing (WGS) assay for molecular residual disease detection (MRD) in circulating tumor DNA to identify early-stage colon cancer patients who are at increased risk of recurrence after surgery or adjuvant chemotherapy. The research-use-only assay is suitable for clinical applications such as precision monitoring for clinical trial enrichment strategies and therapeutic response assessment, and can be applied across solid tumors, Labcorp said. The assay defines a tumor-informed MRD signature using WGS of tumor DNA, germline DNA from buffy coat, and cell-free DNA collected at the landmark time point, according to the company's website. These data are analyzed with a proprietary machine learning algorithm to identify thousands patient-specific somatic tissue variants, creating a signature that can be tracked over time to determine ctDNA status.

The new assay complements the targeted Labcorp Plasma Focus assay and Labcorp Plasma Complete comprehensive profiling solution. All three assays were developed by Personal Genome Diagnostics (PGDx), a Labcorp company, and are performed in PGDx's Baltimore-based CAP-accredited and CLIA-certified laboratory.

Bio-Rad ddPlex ESR1 Mutation Detection Kit

Bio-Rad Laboratories has launched its first ultrasensitive multiplexed digital PCR assay, the ddPlex ESR1 Mutation Detection Kit to aid translational research, therapy selection, and disease monitoring. Designed for use on the Bio-Rad QX600 Droplet Digital PCR System, this research-use assay enables simultaneous detection, discrimination, and absolute quantification of seven known relevant ESR1 mutations in a single well with analytical sensitivity down to 0.01 percent variant allele fraction. The kit includes controls and enables same-day results from either circulating tumor DNA from plasma or DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples. The assay is the first to license NuProbe's allele enrichment technology under a previously announced collaboration.

Qiagen QiAcuity dPCR PanCancer Kits and QiaSeq Targeted RNA-seq Panel for T-Cell Receptors

Qiagen has launched its QiAcuity dPCR PanCancer Kits and QiaSeq Targeted RNA-seq Panel for T-Cell Receptors.

QiAcuity dPCR PanCancer Kits use the company's QiAcuity digital PCR system to simultaneously detect multiple EGFR and BRAF hallmark mutations with high sensitivity. Researchers can use the kits to pre-screen samples before analyzing them with next-generation sequencing (NGS), for example, or for monitoring cancer cells, Qiagen said. The technology has the potential to be adapted to identify other genes associated with cancer risk, Qiagen added.

The new QiaSeq Targeted RNA-seq Panel for T-cell receptors uses unique molecular indices with QiaSeq enrichment technology to facilitate ultrasensitive and accurate characterization of the immune repertoire in humans and mice from low-input and FFPE samples. It enables targeted NGS detection of the following human or mouse expressed T-cell receptors: TCR-alpha, TCR-beta, TCR-gamma, and TCR-delta. This library prep kit is designed to accelerate research into areas such as how the T-cell receptor repertoire in cancer can be used as a biomarker and how the repertoire of tumor-infiltrating T cells can improve the understanding of tumor behavior, Qiagen said.

Element Biosciences Aviti24 and Teton Chemistry

Element Biosciences has begun taking orders for Aviti24, its instrument for next-generation sequencing and multiomic cell profiling. 

Aviti24 allows researchers to simultaneously examine DNA, RNA, proteins, phosphoproteins, and cell structure using the company's Teton chemistry. One run can profile up to 1 million cells in less than 24 hours, the company said. Pre-order list pricing for the instrument is $424,000 or as an upgrade to existing Aviti placements for $150,000. Prior to June 30, 2024, customers can save $50,000 by pre-ordering Aviti24 as part of their purchase. The platform will be shipped by the end of the year.

The instrument will launch with four fixed panels. Two panels will enable deep profiling of the MAPK signaling pathway to investigate basic cancer biology and therapeutic response and resistance. The other two panels will enable human immune profiling and neuroscience applications, respectively. Teton chemistry can also be used to culture cells in a 12-well format.

Takara Bio Shasta Single-Cell System

Takara Bio has launched the Shasta Single-Cell System, an automated, high-throughput platform for biomarker discovery in oncology research.

The system enables whole-genome DNA amplification assays in up to 1,500 single cells per run. For total RNA-seq applications, Shasta enables up to 100,000 cells per run. The highest sensitivity mRNA-Seq kit offers full-length transcript coverage for up to 1,500 cells per run.

The company has launched an early-access program and is accepting orders for shipment at the end of the second quarter.

Bruker Canopy Biosciences CellScape Whole-Slide Imaging Chamber

Bruker's Canopy Biosciences has launched a whole-slide imaging chamber for its CellScape Precise spatial multiplexing platform. The chamber features a total imaging area of 710 mm2 and helps reduce reagent volumes required per sample. It converts any standard microscope slide into a microfluidic chamber with integrated flow diverters to deliver reagents across tissue samples. The expanded area facilitates simultaneous staining of large tissue sections or multiple samples on the same slide, increasing throughput and flexibility, the company said.

Mission Bio: Sample Multiplexing for Tapestri

Mission Bio is introducing sample multiplexing for its Tapestri single-cell DNA and protein analysis platform. Sample multiplexing can be achieved by cell hashing with antibody oligo conjugates from BioLegend or through genotyping with genetic information obtained through bulk sequencing. Benefits include higher throughput and lower costs per sample. Samples are automatically de-multiplexed in the Tapestri Pipeline software.

Nonacus Galeas Tumor

Genetic testing company Nonacus has launched its comprehensive genomic profiling test Galeas Tumor. The next-generation sequencing assay combines targeted panels covering 519 genes with a linked bioinformatics platform for variant calling. The test joins Nonacus' larger portfolio of clinical cancer tests including Galeas Hereditary Plus and Galeas Bladder.

LGC Clinical Diagnostics Seraseq cfDNA NIPT Reference Materials

LGC Clinical Diagnostics has launched Seraseq Antepartum and Postpartum T21 Male and 22q11 Male cfDNA Reference Materials, designed specifically for noninvasive prenatal testing (NIPT) of fetal trisomy 21 (Down syndrome) and microdeletion 22q11 (DiGeorge syndrome). These products enable dilution of the fetal fraction to perform limit of detection studies and analytical validation. Users can also monitor their assay performance at a fetal fraction level of their choice. Derived from naturally occurring matched maternal and fetal circulating cell-free DNA, these reference materials can be used for assay development, validation, verification, analysis, and routine monitoring of test performance, LGC said. The materials are supplied as purified cfDNA in 0.1X TE buffer for ease of use during library preparation, the company added.

For more recently launched products and services, please visit the New Products page on our website.